English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

When discovered, anti-tuberculosis drugs were always administered in Daily-doses; it worked wonders! Later, studies claimed these drugs could cure even in thrice-weekly doses (intermittently). Not everyone believed that. Three Reviews (Cochrane, Thorax, Azhar) appear unconvinced! Also, most nations (including 20 High TB Burden Countries) practice time-tested Daily dosing! INDIA adopted a unique low-cost, thrice-weekly regimen around 2000. During 15 years, under national program, Thrice-weekly doses have been administered to 15 million TB patients, self-claiming 85% success. To revisit long-term outcome of all registered patients in a district; identify the one, who didn't achieve long-lasting recovery with a single course, was later found re-registered for a second innings; his name figures twice in national registry (a Repeater). Author heads District Tuberculosis Center, Faridabad, India; monitors thousands of current/ex-patients on Thrice-weekly regimen. By providence, he enjoys unique access to registered patients, data, district TB-workers. Two methods of data collection: 1. Author motivated district work-force; jointly conducted systematic Retrospective Record Review of hand-written registers of past 15 years, one at a time—thus identified over 1,575 Repeaters. 2. Author has been conducting ongoing Clinical Audit in his busy TB OPD for 6 years. He is able to cherry-pick (average) one Repeater per day; thus tracked 3,100 Repeaters—about half come in from Delhi's premier TB institutes, duly diagnosed, referred in for local registration for Re-treatment. Long-term fate of 36,785 registered TB patients could be analyzed. 4,675 patients observed to have returned sick, meriting Re-registration, Re-treatment; thus over 12.7 % registered twice/thrice (names, unique govt. ID's, irrefutable evidence enclosed)—an adverse outcome, unreported thus far—a bubble. Besides, study recorded 1,590 (5%) Deaths; 2,590 (8%) Defaulters. Under India's routine program conditions, Thrice-weekly regimen is ineffective. Too many (12.7%) patients come back sick, which may promote drug-resistance on industrial scale! A global threat!

Fully Intermittent, Thrice-Weekly Dose of Anti-Tuberculosis Drugs; Their Efficacy under Routine Program Conditions of India